Advertisement

Breast Cancer Oncology

Immunogenic Triple-Negative Breast Cancer Identified With Tumor-Infiltrating Lymphocytes

Sep 19, 2022

Patients with triple-negative breast cancer (TNBC) who harbor more than 40% tumor-infiltrating lymphocytes in their tumor respond well to neoadjuvant immune checkpoint blockade, results from the phase...

OS Benefit With Abemaciclib for HR-positive/HER2-Negative Advanced Breast Cancer

Sep 14, 2022

Results from the second interim analysis of MONARCH 3 show that overall survival is numerically longer with abemaciclib plus a non-steroidal aromatase inhibitor (NSAI) versus placebo plus a NSAI in th...

#VisualAbstract: Capivasertib in Addition to Fulvestrant Improves Progression-Free Survival in ER+ Advanced Breast Cancer

Aug 16, 2022

Click to read this study in The Lancet Oncology. ...

#VisualAbstract: Addition of Denosumab to Neoadjuvant Paclitaxel Does Not Improve Complete Response Rate in Breast Cancer

Aug 10, 2022

Click to read this study in JAMA Oncology. ...

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

Aug 05, 2022

Click to read this study in The Lancet Oncology. ...

#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer

Jul 28, 2022

  Click to read this study in JAMA.  ...

#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage

Jul 21, 2022

Click to read this study in JAMA Network Open.  ...

#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer

May 19, 2022

Click to read this study in Journal of Clinical Oncology. ...

inDEPTH: Who Are the Women With Breast Cancer Survival Rates Near 100%?

May 16, 2022

...

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

May 04, 2022

Click to read this study in The Lancet Oncology. ...

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

Apr 05, 2022

Click to read this study in JAMA Oncology. ...

Subgroup analyses demonstrate consistent OS benefit of ribociclib in patients with locally advanced/metastatic HR-positive/HER2-negative breast cancer

Dec 15, 2021

In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved overall survival (OS) in post-menopausal patients with locally advanced/metastatic HR-positive/HER2-neg...

Elacestrant may improve outcomes for patients whose metastatic breast cancer progressed on prior endocrine therapy

Dec 15, 2021

According to the first results of the EMERALD trial, elacestrant, the first oral selective estrogen receptor degrader, shows clinical benefit over standard endocrine therapy in patients with ER-positi...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab robustly benefits EFS in patients with early triple-negative breast cancer

Dec 15, 2021

Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy follow...

Single-cell spatial analysis may help predict response to neoadjuvant immunotherapy in triple-negative breast cancer

Dec 15, 2021

A next-generation technology allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME). In the NeoTRIPaPDL1 trial, it provid...

Addition of adjuvant palbociclib to standard endocrine therapy does not improve outcomes in patients with early HR-positive breast cancer

Dec 15, 2021

Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with advanced/metastatic HR-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial shows no benefit...

Using genomics to match treatments improves outcomes for certain patients with metastatic breast cancer

Dec 15, 2021

The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of...

Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors.

Dec 15, 2021

The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings in ER-posi...

Black women are more likely to develop lymphedema following breast cancer treatment

Dec 15, 2021

Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results of a prospe...

Promising anti-tumour activity of the CDK7-inhibitor samuraciclib (plus fulvestrant) in pre-treated ER-positive/HER2-negative metastatic breast cancer

Dec 15, 2021

Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human ...